Physician profile
George A Kramer
NPI 1720056443
$55,279.14
in general payments reported to CMS, 2019-2025
28 companies · $667 in 2025
The $667 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $5,991 · 2021: $5,671 · 2022: $5,715 · 2023: $15K · 2024: $8,411 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $3,799 · Travel and Lodging: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,298.00 |
| Food and Beverage | $3,799.41 |
| Travel and Lodging | $269.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $50,348.12 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $671.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $551.90 | 2019-2025 | Jardiance |
| Heartflow, INC. | $391.67 | 2022-2024 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $372.57 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $330.55 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $301.19 | 2022-2025 | Verquvo |
| Esperion Therapeutics, INC. | $281.29 | 2020-2025 | Nexletol |
| Boston Scientific Corporation | $229.31 | 2019-2024 | Avvigo Guidance System |
| Amgen INC. | $210.49 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $203.57 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.98 | 2019-2025 | Lifevest |
| Medtronic, INC. | $188.47 | 2023-2024 | Symplicity G3, Onyx Frontier |
| Cvrx, INC. | $158.52 | 2023 | Barostim Neo System |
| Amarin Pharma, INC. | $131.59 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $108.07 | 2022-2025 | |
| W. L. Gore & Associates, INC. | $106.68 | 2020-2021 | |
| Novo Nordisk INC | $102.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $92.00 | 2025 | Xience Skypoint |
| Philips North America LLC | $82.25 | 2023 | |
| Sanofi-Aventis U.S. LLC | $67.01 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $61.84 | 2024-2025 | Opsumit, Uptravi |
| Celgene Corporation | $41.43 | 2023-2024 | Zeposia |
| Edwards Lifesciences Corporation | $26.18 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kowa Pharmaceuticals America, INC. | $15.67 | 2021 | |
| Medtronic Vascular, INC. | $13.06 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.